Case-control studies evaluated the association of FGF23 concentrations with ovarian cancer stage [16] and of various FGF single nucleotide polymorphisms (SNPs) with cancer development risk, survival, and therapeutic response [18]. This evidence concerns the gene FGF23 and ovarian cancer.